3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia
5
Multiple Myeloma
4
Neoplasms, Plasma Cell
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Leukemia, Promyelocytic, Acute
2
Leukemia, Myeloid, Acute
2
Blast Crisis
2
Skin Neoplasms
1
Oligodendroglioma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Carcinoma, Basal Cell
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
3
fludarabine
3
Cyclophosphamide
3
Ipilimumab
2
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
sargramostim
1
reolysin
1
poly ICLC
1
peginterferon alfa-2a
1
osimertinib
1
gusacitinib
1
fludarabine phosphate
1
eprenetapopt
1
epacadostat
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vorinostat
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Poly I-C
1
Nivolumab
1
Monatide (IMS 3015)
1
Methods
1
MAPRE1 protein, human
1
Interleukin-2
1
Interleukin-15
1
Interleukin-12
1
IT-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Skin Neoplasms
×
Arsenic Trioxide
×
Clear all
NCT01791894
2018-06-08
ATO
Stanford University
Phase 1/2
Completed
5 enrolled
9 charts